Nakanishi (7716) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Aug, 2026Executive summary
Achieved double-digit sales growth across all business segments, with notable strength in Japan's Dental and Surgical businesses and all segments posting double-digit revenue growth.
Consolidated net sales rose 20.5% year-over-year to ¥47,234 million, supported by yen depreciation and M&A contributions from Acra Cut and Intech.
EBITDA increased 22.9% year-over-year to ¥12,769 million, with operating income up 32.0% to ¥10,012 million and net income attributable to owners of parent up 132.0% to ¥8,144 million.
Full-year financial forecast revised upward, with operating, ordinary, and net profit expected to reach record highs (excluding prior year one-off gains).
Enhanced shareholder returns with a higher share repurchase limit and a two-for-one stock split effective October 1, 2026.
Financial highlights
Q2 FY2026 net sales: ¥47,234M (+20.5% YoY); gross profit: ¥27,424M (+18.7% YoY); EBITDA: ¥12,769M (+22.9% YoY); operating profit: ¥10,012M (+32.0% YoY); net profit: ¥8,144M (+132.0% YoY); EPS: ¥98.07 (+67.1% YoY).
Forex impact added ¥2,884M to net sales YoY.
All segments posted double-digit sales growth: Dental (+14.6%), DCI (+23.6%), Surgical (+53.4%), Industrial (+28.6%).
Regional sales growth: Japan (+25.2%), North America (+25.7%), Europe (+23.2%), Asia (+9.8%), Others (+4.2%).
Total assets increased to ¥174,551M, and net assets to ¥122,009M as of June 30, 2026.
Outlook and guidance
FY2026 net sales forecast revised to ¥94,480M (+16.4% YoY); EBITDA ¥24,340M (+22.3% YoY); operating profit ¥16,215M (+15.0% YoY); net profit ¥13,544M (+21.0% YoY).
EPS forecast for FY2026 is ¥81.55 post-stock split (¥163.10 pre-split).
Assumed exchange rates: ¥155/USD, ¥180/EUR for 2H.
All business segments expected to continue growth, with Dental and DCI leading.
Latest events from Nakanishi
- Q1 2026 net income soared 803.9% on 21.3% sales growth, with all segments posting strong gains.7716
Q1 2026 - Acquisition boosts U.S. market share and raises FY2026 sales and profit forecasts.7716
Acquisition presentation - Net sales up 5.4% YoY, but DCI impairment led to a net loss; record sales and profit forecast for FY2026.7716
Q4 2025 - Net sales up 3.8% YoY, but EBITDA and net income declined; guidance unchanged.7716
Q3 2025 - Surgical growth offset flat sales, but net income dropped 50% amid currency headwinds.7716
Q2 2025 - Sales surged 37.4% but net profit dropped 63.7%; outlook and dividend steady.7716
Q3 2024 - Sales surged 36.4% year-over-year, but net income declined 11.9% amid mixed segment results.7716
Q2 2024 - Sales rose, but profits plunged on forex and tax hits; outlook lowered amid global risks.7716
Q1 2025 - Record sales, sharp profit drop; FY2025 sees higher dividend and cautious outlook.7716
Q4 2024